HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

BACKGROUND: Gastric cancer (GC) is a leading cause of cancer deaths worldwide. Since the approval of trastuzumab, targeted therapies are emerging as promising treatment options for the disease. This study aimed to explore the molecular segmentation of several known therapeutics targets, human epider...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Liu, Y J, Shen, D, Yin, X, Gavine, P, Zhang, T, Su, X, Zhan, P, Xu, Y, Lv, J, Qian, J, Liu, C, Sun, Y, Qian, Z, Zhang, J, Gu, Y, Ni, X
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2014
Pynciau:
Translational Therapeutics
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950883/
https://ncbi.nlm.nih.gov/pubmed/24518603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.61
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg